Your browser doesn't support javascript.
loading
Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole.
Fernández, Marisa Liliana; Marson, Maria Elena; Ramirez, Juan Carlos; Mastrantonio, Guido; Schijman, Alejandro Gabriel; Altcheh, Jaime; Riarte, Adelina Rosa; Bournissen, Facundo García.
Afiliação
  • Fernández ML; Instituto Nacional de Parasitología Dr M Fatala Chabén, Buenos Aires, Argentina.
  • Marson ME; Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina.
  • Ramirez JC; Laboratorio de Biología Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Buenos Aires, Argentina.
  • Mastrantonio G; Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina.
  • Schijman AG; Laboratorio de Biología Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Buenos Aires, Argentina.
  • Altcheh J; Hospital de Niños Ricardo Gutiérrez, Buenos Aire, Argentina.
  • Riarte AR; Instituto Nacional de Parasitología Dr M Fatala Chabén, Buenos Aires, Argentina.
  • Bournissen FG; Hospital de Niños Ricardo Gutiérrez, Buenos Aire, Argentina.
Mem Inst Oswaldo Cruz ; 111(3): 218-21, 2016 Mar.
Article em En | MEDLINE | ID: mdl-26982179
Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tripanossomicidas / Trypanosoma cruzi / Doença de Chagas / Nitroimidazóis Tipo de estudo: Guideline / Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mem Inst Oswaldo Cruz Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Argentina País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tripanossomicidas / Trypanosoma cruzi / Doença de Chagas / Nitroimidazóis Tipo de estudo: Guideline / Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mem Inst Oswaldo Cruz Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Argentina País de publicação: Brasil